

Raptor Pharmaceutical Corp
Form 8-K
November 06, 2012
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2012

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

Delaware 000-25571 86-0883978
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

9 Commercial Blvd., Suite 200, Novato, California 94949
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (415) 382-8111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Item 8.01 Other Events.

On November 5, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, presented on Saturday, November 3rd a "Late Breaking" poster entitled "Extended Treatment with RP 103 in Patients with Nephropathic Cystinosis" at Kidney Week 2012, presenting data from the Company's RP103 (cysteamine bitartrate delayed-release) extension study.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit		Filed Here Incorporated by Reference with Form	File No.	Exhibit	Filing Date	Filed By
No.	Exhibit Description					
99.1	Press release issued by the Company dated as of November 5, 2012	X				

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: November 5, 2012 By: /s/ Christopher M. Starr, Ph.D.
Name: Christopher M. Starr, Ph.D.
Title: Chief Executive Officer and Director

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit	Exhibit Description	Filed Here Incorporated by Reference with Form File No. Exhibit Filing Date	Filed By
99.1	Press release issued by the Company dated as of November 5, 2012	X	